Clin2
NCT07018544Likely a fitEnrolling by invitation

Wegovy safety and effectiveness study in Korea

Obesity and Overweight

Treatments studied

Part of Hormones & metabolism clinical trials.

This study watches how Wegovy (semaglutide) works and its side effects when given by doctors to patients with obesity or overweight in South Korea. It is not testing a new drug, but collecting information from routine care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
840 people
Ages
19 years and older
Study type
Observational

Who can take part

  • You are an adult aged 19 or older.
  • You have obesity or are overweight and your doctor has decided to prescribe Wegovy for you.
  • You have not taken Wegovy or any semaglutide medicine before.
  • You are not allergic to semaglutide or any of its ingredients.
  • If you could become pregnant, you are using effective birth control and are not pregnant or breastfeeding.
  • You are able to understand and cooperate with the study procedures.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06856291Recruiting
Semaglutide for obesity with different insulin resistance levels

This study tests whether semaglutide (a weight-loss medication) works differently in people with varying degrees of insulin resistance (how well your body uses sugar). If you are obese without diabetes, you may be able to join.

Aarau, Canton of Aargau
NCT07280221Enrolling by invitation
Wegovy real-world weight loss study in Korea

This study tracks how well Wegovy (a once-weekly injection for weight loss) works for people in Korea who are just starting the medication. It helps doctors understand real-world results outside of a research clinic.

Daejeon
NCT06738979Not yet recruiting· Phase 3
Comparing semaglutide injection to Wegovy® for weight loss

This study tests a new injectable medication (semaglutide) compared to the approved drug Wegovy® for weight loss in people with obesity. It may help you lose weight if you have struggled to keep weight off with diet alone.

Hefei, Anhui
NCT07055607Enrolling by invitation
Real-world study of Wegovy for weight management

This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.

Barcelona
NCT06633783Not yet recruiting· Phase 3
Semaglutide injection for weight loss study

This study tests an injectable medication called semaglutide to help with weight loss in people with a BMI of 28 or higher who have struggled to lose weight before. It compares the study drug to a similar approved weight loss medicine (Wegovy).

Xuancheng, Anhui
NCT07036172Recruiting· Phase 3
Semaglutide vs Wegovy for weight loss in Chinese adults

This trial compares a semaglutide injection to the already-approved weight loss drug Wegovy in Chinese adults with obesity. It aims to see if the new option works just as well to help people lose weight.

Beijing

Hear when a new Obesity and Overweight trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.